23Andme Therapeutics宣佈在2024年ASCO年會上發佈了23Me-00

快訊 · 06/03 20:00

23Andme Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23Me-00610, Targeting Cd200R1, at the 2024 Asco Annual Meeting

23Andme Therapeutics宣佈在2024年ASCO年會上發佈了23Me-00610針對Cd200R1的積極初步2期安全和有效性結果